{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:47:05Z","timestamp":1794361625811,"version":"4.9.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-89408-z","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T07:05:26Z","timestamp":1739171126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes"],"prefix":"10.1038","volume":"15","author":[{"given":"Brandon","family":"Havranek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Redfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Halegoua-DeMarzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"89408_CR1","doi-asserted-by":"publisher","first-page":"530","DOI":"10.4254\/wjh.v10.i8.530","volume":"10","author":"Q Li","year":"2018","unstructured":"Li, Q. et al. Current status of imaging in nonalcoholic fatty liver disease. World J. Hepatol. 10, 530\u2013542 (2018).","journal-title":"World J. Hepatol."},{"key":"89408_CR2","doi-asserted-by":"crossref","unstructured":"Lambrecht, J. & Tacke, F. Controversies and opportunities in the use of inflammatory markers for diagnosis or risk prediction in fatty liver disease. Front. Immunol. ;11. (2021).","DOI":"10.3389\/fimmu.2020.634409"},{"key":"89408_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/livers2040022","volume":"2","author":"A Khan","year":"2022","unstructured":"Khan, A. et al. Risk prevention and health promotion for non-alcoholic fatty liver diseases (NAFLD).Livers 2, 264\u2013282. (2022).","journal-title":"Livers"},{"key":"89408_CR4","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.cgh.2021.11.004","volume":"20","author":"ZM Younossi","year":"2022","unstructured":"Younossi, Z. M. et al. Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver Disease across the World: Data from the global non-alcoholic steatohepatitis (NASH)\/ non-alcoholic fatty liver Disease (NAFLD) Registry. Clin. Gastroenterol. Hepatol. 20, 2296\u20132306e6 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"89408_CR5","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","volume":"110","author":"P Kasper","year":"2021","unstructured":"Kasper, P. et al. NAFLD and cardiovascular diseases: A clinical review. Clin. Res. Cardiol. 110, 921\u2013937 (2021).","journal-title":"Clin. Res. Cardiol."},{"key":"89408_CR6","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne, C. D. & Targher, G. NAFLD: A multisystem disease. J. Hepatol. 62, S47\u2013S64 (2015).","journal-title":"J. Hepatol."},{"key":"89408_CR7","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"EASL\u2013EASD\u2013EASO Clinical Practice","year":"2016","unstructured":"EASL\u2013EASD\u2013EASO Clinical Practice. Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388\u20131402 (2016).","journal-title":"J. Hepatol."},{"key":"89408_CR8","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker, D. J. & Nauck, M. A. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696\u20131705 (2006).","journal-title":"Lancet"},{"key":"89408_CR9","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl. J. Med. 384, 1113\u20131124 (2021).","journal-title":"N Engl. J. Med."},{"key":"89408_CR10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/postgradmedj-2019-137186","volume":"96","author":"KH Sheahan","year":"2020","unstructured":"Sheahan, K. H., Wahlberg, E. A. & Gilbert, M. P. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad. Med. J. 96, 156\u2013161 (2020).","journal-title":"Postgrad. Med. J."},{"key":"89408_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet 394, 121\u2013130 (2019).","journal-title":"Lancet"},{"key":"89408_CR12","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein, H. C. et al. Cardiovascular and renal outcomes with Efpeglenatide in Type 2 diabetes. N Engl. J. Med. 385, 896\u2013907 (2021).","journal-title":"N Engl. J. Med."},{"key":"89408_CR13","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): A double-blind, randomised placebo-controlled trial. Lancet 392, 1519\u20131529 (2018).","journal-title":"Lancet"},{"key":"89408_CR14","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman, R. R. et al. Effects of once-weekly Exenatide on Cardiovascular outcomes in type 2 diabetes. N Engl. J. Med. 377, 1228\u20131239 (2017).","journal-title":"N Engl. J. Med."},{"key":"89408_CR15","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer, M. A. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl. J. Med. 373, 2247\u20132257 (2015).","journal-title":"N Engl. J. Med."},{"key":"89408_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Liraglutide and Cardiovascular outcomes in type 2 diabetes. N Engl. J. Med. 375, 311\u2013322 (2016).","journal-title":"N Engl. J. Med."},{"key":"89408_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-021-01584-3","volume":"28","author":"CT Ruff","year":"2022","unstructured":"Ruff, C. T. et al. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: A non-inferiority randomized controlled trial. Nat. Med. 28, 89\u201395 (2022).","journal-title":"Nat. Med."},{"key":"89408_CR18","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl. J. Med. 375, 1834\u20131844 (2016).","journal-title":"N Engl. J. Med."},{"key":"89408_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain, M. et al. Oral Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl. J. Med. 381, 841\u2013851 (2019).","journal-title":"N Engl. J. Med."},{"key":"89408_CR20","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653\u2013662 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"89408_CR21","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1111\/dom.15058","volume":"25","author":"DK McGuire","year":"2023","unstructured":"McGuire, D. K. et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: Design and baseline characteristics of < scp > SOUL, a randomized trial. Diabetes Obes. Metab. 25, 1932\u20131941 (2023).","journal-title":"Diabetes Obes. Metab."},{"key":"89408_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. An introduction to Propensity score methods for reducing the effects of confounding in Observational studies. Multivar. Behav. Res. 46, 399\u2013424 (2011).","journal-title":"Multivar. Behav. Res."},{"key":"89408_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2014.06.006","volume":"236","author":"SK Kunutsor","year":"2014","unstructured":"Kunutsor, S. K., Apekey, T. A. & Khan, H. Liver enzymes and risk of cardiovascular disease in the general population: A meta-analysis of prospective cohort studies. Atherosclerosis 236, 7\u201317 (2014).","journal-title":"Atherosclerosis"},{"key":"89408_CR24","doi-asserted-by":"publisher","first-page":"e237188","DOI":"10.1001\/jamanetworkopen.2023.7188","volume":"6","author":"A Krishnan","year":"2023","unstructured":"Krishnan, A. et al. Cardiovascular outcomes and Mortality after bariatric surgery in patients with nonalcoholic fatty liver disease and obesity. JAMA Netw. Open. 6, e237188 (2023).","journal-title":"JAMA Netw. Open."},{"key":"89408_CR25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/hep.31726","volume":"74","author":"H Hagstr\u00f6m","year":"2021","unstructured":"Hagstr\u00f6m, H. et al. Administrative coding in electronic health care record-based research of NAFLD: An expert panel consensus statement. Hepatology 74, 474\u2013482 (2021).","journal-title":"Hepatology"},{"key":"89408_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","volume":"4","author":"GM Sullivan","year":"2012","unstructured":"Sullivan, G. M. & Feinn, R. Using effect size\u2014or why the P value is not enough. J. Grad Med. Educ. 4, 279\u2013282 (2012).","journal-title":"J. Grad Med. Educ."},{"key":"89408_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s12055-020-01108-7","volume":"37","author":"SV Deo","year":"2021","unstructured":"Deo, S. V., Deo, V. & Sundaram, V. Survival analysis\u2014part 2: Cox proportional hazards model. Indian J. Thorac. Cardiovasc. Surg. 37, 229\u2013233 (2021).","journal-title":"Indian J. Thorac. Cardiovasc. Surg."},{"key":"89408_CR28","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3390\/ijms24021703","volume":"24","author":"R Nevola","year":"2023","unstructured":"Nevola, R. et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int. J. Mol. Sci. 24, 1703 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"89408_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","volume":"7","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A., Byrne, C. D. & Targher, G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review. Lancet Gastroenterol. Hepatol. 7, 367\u2013378 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"89408_CR30","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.3390\/ijms21165722","volume":"21","author":"M Kojima","year":"2020","unstructured":"Kojima, M. et al. Glucagon-like Peptide-1 receptor agonist prevented the Progression of Hepatocellular Carcinoma in a mouse model of nonalcoholic steatohepatitis. Int. J. Mol. Sci. 21, 5722 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"89408_CR31","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.ajpath.2012.07.015","volume":"181","author":"NA Gupta","year":"2012","unstructured":"Gupta, N. A. et al. The Glucagon-Like Peptide-1 receptor agonist exendin 4 has a protective role in Ischemic Injury of lean and steatotic liver by inhibiting cell death and Stimulating Lipolysis. Am. J. Pathol. 181, 1693\u20131701 (2012).","journal-title":"Am. J. Pathol."},{"key":"89408_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.21006","volume":"43","author":"X Ding","year":"2006","unstructured":"Ding, X. et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis inob\/ob mice. Hepatology 43, 173\u2013181 (2006).","journal-title":"Hepatology"},{"key":"89408_CR33","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/hep.23569","volume":"51","author":"NA Gupta","year":"2010","unstructured":"Gupta, N. A. et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51, 1584\u20131592 (2010).","journal-title":"Hepatology"},{"key":"89408_CR34","doi-asserted-by":"publisher","first-page":"262","DOI":"10.4093\/dmj.2012.36.4.262","volume":"36","author":"J Lee","year":"2012","unstructured":"Lee, J. et al. GLP-1 receptor agonist and non-alcoholic fatty liver disease. Diabetes Metab. J. 36, 262 (2012).","journal-title":"Diabetes Metab. J."},{"key":"89408_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3803\/EnM.2021.1293","volume":"37","author":"J Lee","year":"2022","unstructured":"Lee, J. et al. Dulaglutide ameliorates Palmitic Acid-Induced hepatic steatosis by activating FAM3A signaling pathway. Endocrinol. Metab. 37, 74\u201383 (2022).","journal-title":"Endocrinol. Metab."},{"key":"89408_CR36","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/mt.2008.198","volume":"16","author":"SL Samson","year":"2008","unstructured":"Samson, S. L. et al. Gene therapy for diabetes: Metabolic effects of Helper-dependent Adenoviral Exendin 4 expression in a Diet-induced obesity mouse model. Mol. Ther. 16, 1805\u20131812 (2008).","journal-title":"Mol. Ther."},{"key":"89408_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.diabres.2015.12.003","volume":"113","author":"S Savvidou","year":"2016","unstructured":"Savvidou, S. et al. Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide. Diabetes Res. Clin. Pract. 113, 125\u2013134 (2016).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"89408_CR38","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/biomedicines10051020","volume":"10","author":"K Errafii","year":"2022","unstructured":"Errafii, K. et al. Comparative transcriptome analysis reveals that Exendin-4 improves steatosis in HepG2 cells by modulating signaling pathways related to lipid metabolism. Biomedicines 10, 1020 (2022).","journal-title":"Biomedicines"},{"key":"89408_CR39","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s11095-013-0986-7","volume":"30","author":"Y Ma","year":"2013","unstructured":"Ma, Y. et al. Synthetic FXR agonist GW4064 prevents Diet-Induced hepatic steatosis and insulin resistance. Pharm. Res. 30, 1447\u20131457 (2013).","journal-title":"Pharm. Res."},{"key":"89408_CR40","doi-asserted-by":"publisher","first-page":"166133","DOI":"10.1016\/j.bbadis.2021.166133","volume":"1867","author":"K Panzitt","year":"2021","unstructured":"Panzitt, K. & Wagner, M. FXR in liver physiology: Multiple faces to regulate liver metabolism. Biochim. Biophys. Acta - Mol. Basis Dis. 1867, 166133 (2021).","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"key":"89408_CR41","first-page":"1","volume":"2019","author":"H Wei","year":"2019","unstructured":"Wei, H. et al. Exendin-4 protects against hyperglycemia-induced cardiomyocyte pyroptosis via the AMPK-TXNIP pathway. J. Diabetes Res. 2019, 1\u201313 (2019).","journal-title":"J. Diabetes Res."},{"key":"89408_CR42","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/j.1464-5491.2012.03699.x","volume":"29","author":"G Derosa","year":"2012","unstructured":"Derosa, G. et al. Exenatide plus metformin compared with metformin alone on \u03b2-cell function in patients with type 2 diabetes. Diabet. Med. 29, 1515\u20131523 (2012).","journal-title":"Diabet. Med."},{"key":"89408_CR43","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.2147\/DDDT.S381546","volume":"19","author":"Q Ren","year":"2022","unstructured":"Ren, Q. et al. An effective glucagon-like Peptide-1 receptor agonists, Semaglutide, improves sarcopenic obesity in obese mice by modulating skeletal muscle metabolism. Drug Des. Devel Ther.  16, 3723\u20133735 (2022).","journal-title":"Drug Des. Devel Ther."},{"key":"89408_CR44","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/jcsm.12434","volume":"10","author":"Y Hong","year":"2019","unstructured":"Hong, Y. et al. Amelioration of muscle wasting by glucagon-like peptide\u20101 receptor agonist in muscle atrophy. J. Cachexia Sarcopenia Muscle. 10, 903\u2013918 (2019).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"89408_CR45","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.cgh.2021.07.010","volume":"20","author":"TG Simon","year":"2022","unstructured":"Simon, T. G., Patorno, E. & Schneeweiss, S. Glucagon-like Peptide-1 receptor agonists and hepatic decompensation events in patients with cirrhosis and diabetes. Clin. Gastroenterol. Hepatol. 20, 1382\u20131393e19 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"89408_CR46","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/liv.14799","volume":"41","author":"S Colosimo","year":"2021","unstructured":"Colosimo, S. et al. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. Liver Int. 41, 731\u2013742 (2021).","journal-title":"Liver Int."},{"key":"89408_CR47","doi-asserted-by":"crossref","unstructured":"Tan, Y. et al. Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes. Front. Endocrinol. (Lausanne) ;13. (2022).","DOI":"10.3389\/fendo.2022.935180"},{"key":"89408_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1100\/2012\/496453","volume":"2012","author":"T Ohki","year":"2012","unstructured":"Ohki, T. et al. The effectiveness of Liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes Mellitus compared to Sitagliptin and Pioglitazone. Sci. World J. 2012, 1\u20138 (2012).","journal-title":"Sci. World J."},{"key":"89408_CR49","doi-asserted-by":"crossref","unstructured":"Carvalho, T. Efruxifermin combined with a GLP-1 receptor agonist reduces liver fat in NASH. Nat. Med. June (2023).","DOI":"10.1038\/d41591-023-00055-1"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89408-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89408-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89408-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T18:44:51Z","timestamp":1739213091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89408-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89408"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89408-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dina Halegoua-DeMarzio: Consultant- Pfizer. Research Grant Support- Intercept, Galectin, BMS, Novo Nordisk, Viking, Pfizer; however, this article is solely the author\u2019s work without any connection with Pfizer, Intercept, Galectin, BMS, Novo Nordisk, and Viking. All other authors have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Only aggregated counts and statistical summaries of de-identified information without any protected health information are received from participating HCOs, and no study-specific activities are performed in these retrospective analyses; therefore, TriNetX federated network has been granted a waiver from the Western institutional review board, including the Thomas Jefferson institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"4947"}}